HCPLive Network


In this edition of Clinical Forum, we asked Cardiology Review editorial board members and an invited guest to comment on the controversial new cholesterol guidelines and risk calculator issued by the American Heart Association (AHA) and American College of Cardiology (ACC) in November 2013.
A review of the relationship between body mass index, metabolic syndrome, and cardiovascular disease and all-cause mortality.
The ACC/AHA cholesterol guideline can be a powerful tool for making multifactorial measures of cardiovascular disease risk assessment, particularly in African American populations, but clinicians should be aware of its limitations.
To produce the greatest impact from the implementation of the new American College of Cardiology and American Heart Association guidelines for the treatment of hypercholesterolemia in the primary prevention of cardiovascular disease (CVD), physicians should counsel patients on the benefits and risks of medication intervention to prevent CVD, but also explain the absolute necessity of regular exercise and abstention from tobacco use.
Darapladib, a novel agent targeting an enzyme known to be associated with increased instability of atherosclerotic plaque, failed to show real-world benefit in a large global trial examining mortality and coronary outcomes.
Study results presented at ACC.14 show treatment with PCSK9 inhibitor evolocumab significantly reduces LDL-cholesterol levels in patients with hypercholesterolemia.
Hypertriglyceridemia Upcoming Events